Patents by Inventor Edward Glazer

Edward Glazer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HBV/HCV virus-like particle
    Patent number: 7439058
    Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: October 21, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Mark Selby, Edward Glazer, Michael Houghton
  • Intracellular production of hepatitis C E1 and E2 truncated polypeptides
    Patent number: 7429385
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: September 30, 2008
    Assignee: Novartis Vaccines & Diagnostics
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Like-kind exchange method
    Publication number: 20050044033
    Abstract: A like-kind exchange method wherein an accommodator acquires a property on behalf of an exchanger and establishes itself as the tax owner of the acquired property by becoming liable to pay on at least a portion of a debt on the acquired property. The accommodator then leases the acquired property to the exchanger with an option to buy. During the term of the lease, the exchanger is free to perform any desired development work on the acquired property. With this procedure, the acquired property is available as a replacement property in a like-kind exchange by the exchanger for longer than the 180 day time limitation imposed by Revenue Procedure 2000-37.
    Type: Application
    Filed: January 12, 2004
    Publication date: February 24, 2005
    Inventors: Andrew Gelson, Edwin Rivera, Edward Glazer, David Marcus
  • HBV/HCV virus-like particle
    Publication number: 20040146529
    Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
    Type: Application
    Filed: November 17, 2003
    Publication date: July 29, 2004
    Applicant: Chiron Corporation
    Inventors: Mark Selby, Edward Glazer, Michael Houghton
  • HBV/HCV virus-like particle
    Patent number: 6740323
    Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: May 25, 2004
    Assignee: Chiron Corporation
    Inventors: Mark Selby, Edward Glazer, Michael Houghton
  • Intracellular production of hepatitis C E1 and E2 truncated polypeptides
    Publication number: 20040001854
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Application
    Filed: February 18, 2003
    Publication date: January 1, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Intracellular production of Hepatitis C E2 polypeptides
    Patent number: 6521423
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: February 18, 2003
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer